Article
Oncology
Elisa Van Raemdonck, G. Floris, P. Berteloot, A. Laenen, I. Vergote, H. Wildiers, K. Punie, P. Neven
Summary: In stage IV breast cancer, the conversion of HER2 status is common and primarily observed in hormone receptor-positive tumors. Patients with a positive-to-negative conversion or negative-to-positive conversion showed significant differences in progression free survival and overall survival compared to patients with consistent HER2 status. This study highlights the importance of re-biopsying metastatic lesions and adjusting treatments based on the latest HER2 results.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Surgery
Jui-Yin Kao, Jui-Hung Tsai, Tzu-Yi Wu, Chien-Kuo Wang, Yao-Lung Kuo
Summary: Discordance in subtype and receptor status between primary and metastatic lesions can impact survival outcomes, especially for ER and PR discordance. Phenotype change may also affect patient survival.
ASIAN JOURNAL OF SURGERY
(2021)
Article
Endocrinology & Metabolism
Shuhui You, Chengcheng Gong, Yi Li, Yizhao Xie, Yumeng Li, Yannan Zhao, Biyun Wang
Summary: In HoR-positive MBC, patients with low and zero HER2 expression have similar clinical characteristics and respond similarly to endocrine treatment, but the chemotherapy effect is worse in the HER2-low patients. Moreover, the transformation of HER2 status from primary to metastatic lesions may have potential influence on chemotherapy outcomes.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Emily I. Holthuis, Gerard T. Vondeling, Josephina G. Kuiper, Vincent Dezentje, Mats Rosenlund, Jetty A. Overbeek, Carolien H. M. van Deurzen
Summary: This study compared clinicopathologic characteristics and survival in breast cancer patients with different levels of HER2 expression. The results showed that in HR-positive patients, those with HER2 IHC0 or HER2-low cancer were older compared to HER2+ patients, while this age difference was not observed in HR-negative patients. The localization of distant metastases differed significantly between HER2 IHC0 or HER2-low and HER2+ cases. Survival rates did not differ markedly by subtypes.
Article
Oncology
Matthew Loft, Sheau Wen Lok, Richard De Boer, Laeeq Malik, Sally Greenberg, Belinda Yeo, Angelyn Anton, Michelle Nottage, Vanessa Wong, Louise Nott, Ian M. M. Collins, Javier Torres, Frances Barnett, Janine M. M. Lombard, Peter Gibbs, Lucy Gately
Summary: The study aimed to investigate the efficacy of combining endocrine therapy (ET) with dual anti-HER2 targeted therapy and chemotherapy in HER2 + /HR + breast cancer patients. The results showed that adding ET during first-line chemotherapy in combination with dual anti-HER2 therapy significantly improved 5-year progression-free survival (PFS) and overall survival (OS), with no significant safety concerns.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Multidisciplinary Sciences
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, Eriseld Krasniqi, Marcello Maugeri-Sacca, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Domenico Sergi, Daniele Marinelli, Giancarlo Paoletti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Nicola Tinari, Antonino Grassadonia, Maria Rosaria Valerio, Rosanna Mirabelli, Maria Agnese Fabbri, Nicola D'Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Icro Meattini, Mirco Pistelli, Francesco Giotta, Vito Lorusso, Carlo Garufi, Antonio Russo, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Angela Vaccaro, Letizia Perracchio, Anna di Benedetto, Theodora Daralioti, Isabella Sperduti, Ruggero De Maria, Angelo Di Leo, Giuseppe Sanguineti, Gennaro Ciliberto, Patrizia Vici
Summary: The study found that patients with HER2-positive mBC with discordant HER2 status in early BC may have different clinical, biological, and prognostic behavior compared to HER2-concordant patients. These patients showed higher expression of estrogen and/or progesterone receptor, lower rate of brain metastases, and longer disease-free interval.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Marissa Meegdes, Khava I. E. Ibragimova, Dorien J. A. Lobbezoo, Ingeborg J. H. Vriens, Loes F. S. Kooreman, Frans L. G. Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. A. E. Pepels, Linda M. H. van de Winkel, Jolien Tol, Joan B. Heijns, Agnes J. van de Wouw, Natascha A. J. B. Peters, Ananda Hochstenbach-Waelen, Marjolein L. Smidt, Sandra M. E. Geurts, Vivianne C. G. Tjan-Heijnen
Summary: This study evaluated the biopsy rate and receptor subtype discordance rate in patients with advanced breast cancer. The study found that the HR+/HER2+ subtype had the highest discordance rate and lowest biopsy rate, highlighting the importance of obtaining a biopsy of metastatic disease.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Melody A. Cobleigh, Charles L. Vogel, Debu Tripathy, Nicholas J. Robert, Susy Scholl, Louis Fehrenbacher, Janet M. Wolter, Virginia Paton, Steven Shak, Gracie Lieberman, Dennis J. Slamon
Summary: Recombinant humanized anti-HER2 monoclonal antibody as a single agent shows durable objective responses and good tolerability in women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jinhao Wang, Yaxin Liu, Yuehua Liang, Yue Zhang, Hang Dong, Tiantian Zheng, Jianjun Yu, Pan Du, Shidong Jia, Bonnie L. L. King, Jing Wang, Xiaoran Liu, Huiping Li
Summary: The determinants of outcome for younger vs. older patients with hormone receptor-positive/HER2-negative metastatic breast cancer were evaluated. The age of patients did not significantly affect the prognosis in this study. These findings support the development of biomarker-driven treatment strategies for these patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
Summary: This study showed that adding everolimus to letrozole with ovarian suppression can lead to longer progression-free survival in tamoxifen-exposed HR+, HER2- metastatic breast cancer patients, especially those with visceral metastasis.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Whitney L. Hensing, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli, Andrew A. Davis
Summary: In this study, the authors analyzed the genetic alterations in circulating tumor DNA of patients with HER2-low metastatic breast cancer. They found a higher rate of PIK3CA mutations in HER2-low patients, but no significant differences in ERBB2 alterations, oncogenic pathways, or prognosis compared to HER2-0 patients. These findings suggest that HER2-low breast cancer does not represent a distinct biological subtype.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Pusztai, Mothaffar F. Rimawi, Rachel Schiff, Grazia Arpino, Sabino De Placido, Aleix Prat, Daniele Generali
Summary: A meta-analysis on first-/second-line ET +/- TT for HR+/HER2-negative MBC showed that combination strategies were more effective than single-agent ET, with CDK4/6-inhibitors + ET being the most effective regimen. Single agent ET demonstrated comparable efficacy with ET+TT combinations in non-visceral and endocrine sensitive diseases, while mTORi-based combinations and PI3Ki + ET showed valid therapeutic options in endocrine-resistant and PIK3CA-mutant tumors. These results reinforce international treatment guidelines and can assist in therapeutic decision-making.
Article
Oncology
Qian Wang, Zhoubo Guo, Zhou Huang, Huiru Sun, Jingyang Zhu, Jinyan Shi, Wencheng Zhang, Desheng Li, Bing Sun
Summary: This study investigated the expression status of ER, PR, and HER2 in breast cancer brain metastases. The results showed that conversion of hormone receptor and HER2 occurred between primary breast tumors, brain metastases, and extra-brain metastases. The conversion rate reached 31% when using a new HER2 categorization.
Article
Pharmacology & Pharmacy
Jie Chen, Jin Zhu, Shuai-Jun Xu, Jun Zhou, Xiao-Fei Ding, Yong Liang, Guang Chen, Hong-Sheng Lu
Summary: TM4SF1 is downregulated in HR(+)HER2(-) breast cancer, and its overexpression suppresses cell proliferation in this cancer subtype.
FRONTIERS IN PHARMACOLOGY
(2022)